Translational NeuroImaging of the CNS: Novel Pathways to Drug Development

被引:14
|
作者
Fox, Gerard B. [1 ]
Chin, Chih-Liang [1 ]
Luo, Feng [1 ]
Day, Mark [1 ]
Cox, Bryan F. [1 ]
机构
[1] Abbott Labs, Global Pharmaceut Res & Dev, Abbott Pk, IL 60064 USA
关键词
POSITRON-EMISSION-TOMOGRAPHY; TRANSGENIC MOUSE MODEL; ALZHEIMERS-DISEASE; PHARMACOLOGICAL MRI; BRAIN ACTIVATION; WHITE-MATTER; HIPPOCAMPAL ATROPHY; GLUCOSE-UTILIZATION; COGNITIVE DECLINE; AMYLOID PLAQUES;
D O I
10.1124/mi.9.6.6
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Scientists engaged in drug discovery and development face many critical issues along the road to identifying the best drug candidates to bring forward for testing in patients. In neuroscience, these challenges can involve particularly demanding questions regarding target engagement, the predict ability of endpoints in animal models, new disease model validation, CNS penetration, and the identification of pharmacodynamic markers. For neurological conditions such as Alzheimer's disease, clinical trials of novel drugs that may modify the course of disease, rather than targeting specific symptoms, add extra layers of complexity. Major studies designed to track the course of a disease increasingly depend on noninvasive, translational imaging. In this brief review, we highlight examples of the new wave of neuroimaging studies that engender useful biomarkers of disease for translational research.
引用
下载
收藏
页码:302 / 313
页数:12
相关论文
共 50 条
  • [21] Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics
    van den Brink, W. J.
    Hankemeier, T.
    van der Graaf, P. H.
    de Lange, E. C. M.
    EXPERT OPINION ON DRUG DISCOVERY, 2018, 13 (06) : 539 - 550
  • [22] Essential CNS Drug Development
    Salomon, Ronald M.
    JOURNAL OF CLINICAL PSYCHIATRY, 2013, 74 (03) : E221 - E221
  • [23] CHALLENGES IN CNS DRUG DEVELOPMENT
    Cha, J. H.
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2014, 85 : A9 - A9
  • [24] Of Mice and Men Bridging the Translational Disconnect in CNS Drug Discovery
    Geerts, Hugo
    CNS DRUGS, 2009, 23 (11) : 915 - 926
  • [25] TRANSLATIONAL RESEARCH AND DRUG DEVELOPMENT
    Benavides, J.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2011, 109 : 2 - 2
  • [26] Developing Novel Treatments for Psychiatric Illnesses: Can Drug Development Tool Qualification Advance CNS Drug Development?
    Brady, Linda
    Davis, Michael
    Pandina, Gahan
    Cannon, Tyrone
    Kolb, Hartmuth
    McPartland, James
    Leptak, Chris
    Horner, Michelle
    Reasner, David
    Lisanby, Sarah
    Graham, Danielle
    Dage, Jeffrey
    Berman, Steven
    NEUROPSYCHOPHARMACOLOGY, 2021, 46 (SUPPL 1) : 41 - 42
  • [27] Editorial: Progress in Translational Neuroimaging: Integrating Pathways, Systems, and Phenomenology in Neurology and Psychiatry
    Stoyanov, Drozdstoy
    Brambilla, Paolo
    FRONTIERS IN PSYCHIATRY, 2020, 11
  • [28] The application of functional neuroimaging in drug development
    Nathan, P.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S5 - S6
  • [29] Strategies for Utilizing Neuroimaging Biomarkers in CNS Drug Discovery and Development: CINP/JS']JSNP Working Group Report
    Suhara, Tetsuya
    Chaki, Shigeyuki
    Kimura, Haruhide
    Furusawa, Makoto
    Matsumoto, Mitsuyuki
    Ogura, Hiroo
    Negishi, Takaaki
    Saijo, Takeaki
    Higuchi, Makoto
    Omura, Tomohiro
    Watanabe, Rira
    Miyoshi, Sosuke
    Nakatani, Noriaki
    Yamamoto, Noboru
    Liou, Shyh-Yuh
    Takado, Yuhei
    Maeda, Jun
    Okamoto, Yasumasa
    Okubo, Yoshiaki
    Yamada, Makiko
    Ito, Hiroshi
    Walton, Noah M.
    Yamawaki, Shigeto
    INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY, 2017, 20 (04):
  • [30] Role of neuroimaging in analgesic drug development
    Lawrence, Jane
    Mackey, Sean C.
    DRUGS IN R&D, 2008, 9 (05) : 323 - 334